Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

129-derived passenger mutations confound phenotype of ACKR1-deficient mice

ABSTRACT: A majority of genetically modified mice carry passenger mutations, originating from the 129-derived embryonic stem (ES) cells, near the targeted gene. Unintended retention of these mutations can introduce confounding phenotypes and affect conclusions. We show that Ackr1-/-129ES mice retained approximately 6 Mb of 129 ES cells-derived genomic material in chromosome 1 near Ackr1 in bone marrow derived monocytes (Mono), nucleated erythroblasts (NECs), and polymorphonucleated neutrophils (PMN), notably affecting the expression of PYHIN genes.

ORGANISM(S): Mus musculus

PROVIDER: GSE256021 | GEO | 2024/09/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

129-derived passenger mutations confound phenotype of ACKR1-deficient mice

Project description:129-derived passenger mutations confound phenotype of ACKR1-deficient mice

| PRJNA1077396 | ENA

Transcriptome analysis of WT and ATRX KO Cast x 129 mouse ES cells

Project description:Analysis of gene expression in WT and ATRX KO Cast x 129 Mouse ES cells

2015-04-16 | GSE59269 | GEO

Passenger Mutations Confound Phenotypes of SARM1-Deficient Mice.

Project description:The Toll/IL-1R-domain-containing adaptor protein SARM1 is expressed primarily in the brain, where it mediates axonal degeneration. Roles for SARM1 in TLR signaling, viral infection, inflammasome activation, and chemokine and Xaf1 expression have also been described. Much of the evidence for SARM1 function relies on SARM1-deficient mice generated in 129 ESCs and backcrossed to B6. The Sarm1 gene lies in a gene-rich region encompassing Xaf1 and chemokine loci, which remain 129 in sequence. We therefore generated additional knockout strains on the B6 background, confirming the role of SARM1 in axonal degeneration and WNV infection, but not in VSV or LACV infection, or in chemokine or Xaf1 expression. Sequence variation in proapoptotic Xaf1 between B6 and 129 results in coding changes and distinct splice variants, which may account for phenotypes previously attributed to SARM1. Reevaluation of phenotypes in these strains will be critical for understanding the function of SARM1.

| S-EPMC7226674 | biostudies-literature

Transcriptome analysis of WT and ATRX KO Cast x 129 mouse ES cells

Project description:Analysis of gene expression in WT and ATRX KO Cast x 129 Mouse ES cells Paired end RNA-seq analysis of PolyA selected RNA and PolyA depeleted RNA from in both wildtype nd ATRX knocked out Castx129 Mouse ES Cells

2015-04-16 | E-GEOD-59269 | biostudies-arrayexpress

Passenger Mutations Confound Interpretation of All Genetically Modified Congenic Mice.

Project description:Targeted mutagenesis in mice is a powerful tool for functional analysis of genes. However, genetic variation between embryonic stem cells (ESCs) used for targeting (previously almost exclusively 129-derived) and recipient strains (often C57BL/6J) typically results in congenic mice in which the targeted gene is flanked by ESC-derived passenger DNA potentially containing mutations. Comparative genomic analysis of 129 and C57BL/6J mouse strains revealed indels and single nucleotide polymorphisms resulting in alternative or aberrant amino acid sequences in 1,084 genes in the 129-strain genome. Annotating these passenger mutations to the reported genetically modified congenic mice that were generated using 129-strain ESCs revealed that nearly all these mice possess multiple passenger mutations potentially influencing the phenotypic outcome. We illustrated this phenotypic interference of 129-derived passenger mutations with several case studies and developed a Me-PaMuFind-It web tool to estimate the number and possible effect of passenger mutations in transgenic mice of interest.

| S-EPMC4800811 | biostudies-literature

miR-129-3p control cilia assembly by regulating CP110 and actin dynamics [miR-129-3p overexpression]

Project description:Primary cilium serves as a cellular “antenna” to sense environmental signals. Ciliogenesis requires the removal of CP110 to convert the mother centriole into the basal body. Actin dynamics is also critical for cilia formation. How these distinct processes are properly regulated remains unknown. Here we show that miR-129-3p, a microRNA conserved in the vertebrates, controlled cilia assembly by down-regulating both CP110 and four proteins critical for actin dynamics, Arp2, Toca1, abLIM1, and abLIM3. Consistently, blocking miR-129-3p repressed cilia formation in cultured mammalian cells, whereas its overexpression potently induced ciliogenesis in proliferating cells and extraordinary cilia elongation. Moreover, inhibition of miR-129-3p in zebrafish embryos suppressed cilia assembly in the Kupffer’s vesicle and pronephric duct, leading to developmental abnormalities including curved body, pericardial oedema, and randomised left-right patterning. Our results thus unravel a novel mechanism that orchestrates both the centriole-to-basal body transition and subsequent cilia assembly via microRNA-mediated posttranscriptional regulations. We want to find the targets of miR-129-3p by overexpressing miR-129-3p oligo or control oligo in hTERT-RPE1 cells. Through microarray analysis we could check the downregulated genes and these genes might be the targets of miR-129-3p.

2012-06-01 | GSE34846 | GEO

Bradyrhizobium diazoefficiens strain:USDA 129 | isolate:USDA 129

Project description:Bradyrhizobium diazoefficiens USDA 129 genome sequencing

| PRJNA1115737 | ENA

Firmicutes bacterium CAG:129

Project description:Firmicutes bacterium CAG:129 overview

| PRJNA207150 | ENA

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Project description:This is a multi-center, open-label, Phase I/II clinical study of MCLA-129 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of MCLA-129.

| 2380882 | ecrin-mdr-crc

Bradyrhizobium sp. UFLA05-129

Project description:Bradyrhizobium sp. UFLA05-129 Genome sequencing

| PRJNA995544 | ENA